| Variable |
Group I: Placebo-Control Group (n=37) |
Group II: Ondansetron Study Group (n=39) |
Overall (n=76) |
| Age, yr (mean ± standard deviation) |
37 ± 11 |
42 ± 14 |
39 ± 13 |
| Body Mass Index (mean ± standard deviation) |
24 ± 3 |
25 ± 3 |
25 ± 3 |
| Sex, n (%) |
|
|
|
| Male |
18 (49) |
21 (54) |
39 (51) |
| Female |
19 (51) |
18 (46) |
37 (49) |
| Race/ethnicity, n (%) |
|
|
|
| Caucasian |
36 (97) |
34 (87) |
70 (92) |
| African american |
-- |
1 (3) |
1 (1) |
| Asian |
-- |
1 (3) |
1 (1) |
| Native american |
-- |
1 (3) |
1 (1) |
| Hispanic |
1 (3) |
2 (5) |
3 (4) |
| Patient Smokes, n (%) |
2 (5) |
2 (5) |
4 (5) |
| History of post-operative nausea/vomiting, n (%) |
5 (13) |
5 (13) |
10 (13) |
| History of intolerance to narcotics, n (%) |
3 (8) |
5 (13) |
8 (11) |
| History of motion sickness, n (%) |
9 (24) |
4 (10) |
13 (17) |
|
